KLIKJARO 15mg

KLIKJARO 15mg is based on tirzepatide, a synthetic peptide that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. Developed as part of a new generation of incretin-based therapeutics, tirzepatide was designed to investigate whether simultaneous activation of two complementary metabolic pathways could produce broader physiological effects than selective GLP-1 receptor activation alone. Scientific interest in tirzepatide has expanded rapidly following large international clinical programmes evaluating its role in obesity and type 2 diabetes. Research has demonstrated coordinated effects across multiple organ systems, including the pancreas, gastrointestinal tract, liver, adipose tissue, kidneys, cardiovascular system and central nervous system. Unlike compounds that act primarily through a single metabolic pathway, tirzepatide influences appetite regulation, insulin secretion, glucagon suppression, gastric emptying and nutrient utilisation simultaneously. Ongoing research continues to explore the molecular mechanisms responsible for these integrated physiological responses.

THE INCRETIN SYSTEM The incretin system plays a fundamental role in regulating glucose homeostasis after food consumption. Following nutrient ingestion, specialised endocrine cells within the small intestine release incretin hormones that communicate with distant organs to coordinate metabolism. The two principal incretin hormones are: • Glucose-dependent insulinotropic polypeptide (GIP) — secreted primarily by K-cells of the proximal small intestine • Glucagon-like peptide-1 (GLP-1) — secreted primarily by L-cells of the distal intestine Together, these hormones contribute to glucose-dependent insulin secretion, regulation of glucagon release, appetite control, gastric motility, energy balance and lipid metabolism. In healthy individuals, the incretin response accounts for a substantial proportion of insulin secretion following oral glucose intake. In people with type 2 diabetes, this physiological response is often diminished, making incretin biology an important area of metabolic research.

DUAL RECEPTOR AGONISM Tirzepatide binds to both GIP and GLP-1 receptors. Although these receptors share similar intracellular signalling pathways, each contributes unique physiological functions. GLP-1 receptor activation primarily influences glucose-dependent insulin secretion, appetite regulation, gastric emptying and glucagon suppression. GIP receptor activation has been investigated for potential effects on beta-cell responsiveness, adipocyte metabolism, lipid handling, nutrient partitioning and energy utilisation. Simultaneous activation appears to produce complementary effects across multiple metabolic tissues. PANCREATIC FUNCTION Within pancreatic islets, tirzepatide enhances insulin secretion only when blood glucose concentrations are elevated. This glucose-dependent mechanism distinguishes incretin therapies from several older glucose-lowering agents. Research has demonstrated improvements in beta-cell responsiveness, insulin secretion efficiency, fasting glucose, postprandial glucose and HbA1c. Several mechanistic studies also suggest reduced beta-cell stress during prolonged treatment. GASTROINTESTINAL EFFECTS GLP-1 receptor activation slows gastric emptying during the initial stages of treatment. This contributes to reduced post-meal glucose excursions, earlier satiety, smaller meal size and reduced caloric intake. Long-term studies suggest that while gastric emptying partially adapts over time, appetite suppression generally persists through central nervous system mechanisms. CENTRAL NERVOUS SYSTEM GLP-1 receptors are distributed throughout several brain regions involved in appetite regulation. Functional MRI investigations have demonstrated altered neural activity within regions associated with food reward, motivation, cravings, satiety and decision making. These neurological adaptations are believed to contribute significantly to reduced daily energy intake observed during clinical trials. The precise contribution of GIP receptor signalling within the central nervous system remains an active area of investigation.

SURPASS PROGRAMME The SURPASS clinical programme evaluated tirzepatide in adults with type 2 diabetes across several international randomised controlled trials. Researchers consistently observed improvements in HbA1c, fasting plasma glucose, body weight, waist circumference and insulin sensitivity. Comparative studies also demonstrated favourable glycaemic outcomes relative to several established glucose-lowering therapies under controlled research conditions. SURMOUNT PROGRAMME The SURMOUNT programme focused primarily on overweight and obesity. Participants receiving tirzepatide alongside structured dietary and physical activity interventions demonstrated substantial reductions in body weight over treatment periods extending beyond one year. Additional observations included improvements in blood pressure, triglycerides, HDL cholesterol, waist circumference and health-related quality of life. These studies continue to inform understanding of long-term metabolic adaptation following sustained incretin receptor activation. BODY COMPOSITION DXA imaging studies indicate that reductions in body weight primarily reflect decreases in adipose tissue, particularly visceral fat. Researchers continue investigating methods to preserve lean body mass during prolonged weight reduction through resistance exercise, increased dietary protein, optimised nutritional strategies and combination interventions. LIVER AND METABOLIC HEALTH Studies have investigated tirzepatide's effects on liver metabolism. Reported observations include improvements in liver fat accumulation, ALT, AST, insulin resistance and inflammatory biomarkers. Dedicated clinical programmes continue evaluating its role in metabolic dysfunction-associated steatotic liver disease (MASLD). CARDIOVASCULAR RESEARCH Beyond glucose regulation, researchers have investigated broader cardiovascular effects. Areas of ongoing study include endothelial function, blood pressure, lipoprotein metabolism, vascular inflammation, major adverse cardiovascular events and heart failure. Several large outcome trials remain ongoing to determine whether metabolic improvements translate into reductions in long-term cardiovascular risk.

Tirzepatide contains structural modifications that prolong systemic exposure. Key pharmacokinetic characteristics: • Administration — subcutaneous • Bioavailability — high • Peak concentration — 24–72 hours • Elimination half-life — approximately 5 days • Steady state — approximately 4 weeks The peptide undergoes proteolytic degradation following metabolism rather than being excreted unchanged. Albumin binding contributes significantly to its prolonged duration of action.

SAFETY PROFILE Across clinical research, gastrointestinal symptoms represent the most frequently reported adverse events: • Nausea • Vomiting • Diarrhoea • Constipation • Reduced appetite • Abdominal discomfort Researchers also monitor for less common events including gallbladder disease, pancreatitis, dehydration, delayed gastric emptying and rare hypersensitivity reactions. Gradual dose escalation is commonly employed within clinical investigations to improve tolerability. RESEARCH LIMITATIONS Despite extensive investigation, important questions remain. Current areas requiring further research include: • Long-term treatment beyond five years • Individual variability in treatment response • Mechanisms underlying sustained appetite regulation • Maintenance of weight reduction following discontinuation • Preservation of lean body mass • Combination therapy approaches

Future research is expected to focus on: • Multi-receptor incretin therapies • Precision medicine approaches • Cardiovascular outcome research • Liver disease (MASLD) • Renal protection • Healthy ageing • Metabolic inflammation • Prediabetes, OSA, PCOS and metabolic syndrome These investigations are expected to further expand understanding of incretin biology and systemic metabolic regulation.